alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# EUR-Lex - 31984D0578 - EN

Avis juridique important

*|*

# 31984D0578

**84/578/EEC: Commission Decision of 14 November 1984 amending Decision 83/423/EEC as regards the list of establishments in Paraguay approved for the purpose of importing fresh meat into the Community **

*
Official Journal L 315 , 05/12/1984 P. 0028 - 0029 Spanish special edition: Chapter 03 Volume 33 P. 0003 Portuguese special edition Chapter 03 Volume 33 P. 0003 *

*****

COMMISSION DECISION

of 14 November 1984

amending Decision 83/423/EEC as regards the list of establishments in Paraguay approved for the purpose of importing fresh meat into the Community

(84/578/EEC)

THE COMMISSION OF THE EUROPEAN

COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community,

Having regard to Council Directive 72/462/EEC of 12 December 1972 on health and veterinary inspection problems upon importation of bovine animals and swine and fresh meat from third countries (1), as last amended by Directive 83/91/EEC (2), and in particular Articles 4 (1) and 18 (1) (a) and (b) thereof,

Whereas a list of establishments in Paraguay, approved for the purpose of the importation of fresh meat into the Community, was drawn up initially by Commission Decision 83/423/EEC (3), as amended by Decision 84/391/EEC (4);

Whereas a routine inspection under Article 5 of Directive 72/462/EEC and Article 3 (1) of Commission Decision 83/196/EEC of 8 April 1983 concerning on-the-spot inspections to be carried out in respect of the importation of bovine animals and swine and fresh meat from non-member countries (5) has revealed that the level of hygiene of one establishment has altered since the last inspection;

Whereas the list of establishments should, therefore, be amended;

Whereas the measures provided for in this Decision are in accordance with the opinion of the Standing Veterinary Committee,

HAS ADOPTED THIS DECISION:

Article 1

The Annex to Decision 83/423/EEC is hereby replaced by the Annex to this Decision.

Article 2

This Decision is addressed to the Member States.

Done at Brussels, 14 November 1984.

For the Commission

Poul DALSAGER

Member of the Commission

(1) OJ No L 302, 31. 12. 1972, p. 28.

(2) OJ No L 59, 5. 3. 1983, p. 34.

(3) OJ No L 238, 27. 8. 1983, p. 39.

(4) OJ No L 211, 8. 8. 1984, p. 23.

(5) OJ No L 108, 26. 4. 1983, p. 18.

ANNEX

LIST OF ESTABLISHMENTS

1.2.3 // // // // Approval No // Establishment // Address // // //

BOVINE MEAT

Slaughterhouses and cutting premises

1.2.3 // // // // 1 // Productos Enfriados SA (PESA) // Zeballos-Cue // 5 // Compañia de Desarrollo Ganadero SA (CODEGA) // Tablada Nueva // 8 // Paraguayan Meat Packers SA (PAMPA) // Asunción // 17 // Compañia Industrial y Ganadera Guarani SA // Fernando de la Mora // // //
Editorial Note on Part 131
Editorial Note: Nomenclature changes to part 131 appear at 63 FR 14035, Mar. 24, 1998.

§ 131.160 Sour cream. ( a ) *Description.* Sour cream results from the souring, by lactic acid producing bacteria, of pasteurized cream. Sour cream contains not less than 18 percent milkfat; except that when the food is characterized by the addition of nutritive sweeteners or bulky flavoring ingredients, the weight of the milkfat is not less than 18 percent of the remainder obtained by subtracting the weight of such optional ingredients from the weight of the food; but in no case does the food contain less than 14.4 percent milkfat. Sour cream has a titratable acidity of not less than 0.5 percent, calculated as lactic acid.
( b ) *Optional ingredients.* ( 1 ) Safe and suitable ingredients that improve texture, prevent syneresis, or extend the shelf life of the product.
( 2 ) Sodium citrate in an amount not more than 0.1 percent may be added prior to culturing as a flavor precursor.
( 3 ) Rennet.
( 4 ) Safe and suitable nutritive sweeteners.
( 5 ) Salt.
( 6 ) Flavoring ingredients, with or without safe and suitable coloring, as follows: ( i ) Fruit and fruit juice (including concentrated fruit and fruit juice).
( ii ) Safe and suitable natural and artificial food flavoring.
( c ) *Methods of analysis.* Referenced methods in paragraph (c) (1) and (2) of this section are from “Official Methods of Analysis of the Association of Official Analytical Chemists,” 13th Ed. (1980), which is incorporated by reference. Copies may be obtained from the AOAC INTERNATIONAL, 481 North Frederick Ave., suite 500, Gaithersburg, MD 20877, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .* ( 1 ) Milkfat content—“Fat—Official Final Action,” section 16.172.
( 2 ) Titratable acidity—“Acidity—Official Final Action,” section 16.023.
( d ) *Nomenclature.* The name of the food is “Sour cream” or alternatively “Cultured sour cream”. The full name of the food shall appear on the principal display panel of the label in type of uniform size, style, and color. The name of the food shall be accompanied by a declaration indicating the presence of any flavoring that characterizes the product, as specified in § 101.22 of this chapter. If nutritive sweetener in an amount sufficient to characterize the food is added without addition of characterizing flavoring, the name of the food shall be preceded by the word “sweetened”.
( e ) *Label declaration.* Each of the ingredients used in the food shall be declared on the label as required by the applicable sections of parts 101 and 130 of this chapter.
[42 FR 14360, Mar. 15, 1977, as amended at 47 FR 11824, Mar. 19, 1982; 49 FR 10092, Mar. 19, 1984; 54 FR 24893, June 12, 1989; 58 FR 2891, Jan. 6, 1993]
§ 211.94 Drug product containers and closures. Cross Reference
Link to an amendment published at 89 FR 51769 , June 18, 2024.
( a ) Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug beyond the official or established requirements.
( b ) Container closure systems shall provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.
( c ) Drug product containers and closures shall be clean and, where indicated by the nature of the drug, sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use. Such depyrogenation processes shall be validated.
( d ) Standards or specifications, methods of testing, and, where indicated, methods of cleaning, sterilizing, and processing to remove pyrogenic properties shall be written and followed for drug product containers and closures.
( e ) *Medical gas containers and closures must meet the following requirements* — ( 1 ) *Gas-specific use outlet connections.* Portable cryogenic medical gas containers that are not manufactured with permanent gas use outlet connections (*e.g.,* those that have been silver-brazed) must have gas-specific use outlet connections that are attached to the valve body so that they cannot be readily removed or replaced (without making the valve inoperable and preventing the containers' use) except by the manufacturer. For the purposes of this paragraph, the term “manufacturer” includes any individual or firm that fills high-pressure medical gas cylinders or cryogenic medical gas containers. For the purposes of this section, a “portable cryogenic medical gas container” is one that is capable of being transported and is intended to be attached to a medical gas supply system within a hospital, health care entity, nursing home, other facility, or home health care setting, or is a base unit used to fill small cryogenic gas containers for use by individual patients. The term does not include cryogenic containers that are not designed to be connected to a medical gas supply system, *e.g.,* tank trucks, trailers, rail cars, or small cryogenic gas containers for use by individual patients (including portable liquid oxygen units as defined at § 868.5655 of this chapter).
( 2 ) *Label and coloring requirements.* The labeling specified at § 201.328(a) of this chapter must be affixed to the container in a manner that does not interfere with other labeling and such that it is not susceptible to becoming worn or inadvertently detached during normal use. Each such label as well as materials used for coloring medical gas containers must be reasonably resistant to fading, durable when exposed to atmospheric conditions, and not readily soluble in water.
[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51932, Sept. 8, 2008; 81 FR 81697, Nov. 18, 2016]
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1372 Insoluble glucose isomerase enzyme preparations. ( a ) Insoluble glucose isomerase enzyme preparations are used in the production of high fructose corn syrup described in § 184.1866. They are derived from recognized species of precisely classified nonpathogenic and nontoxicogenic microorganisms, including *Streptomyces rubiginosus, Actinoplanes missouriensis, Streptomyces olivaceus, Streptomyces olivochromogenes,* and *Bacillus coagulans,* that have been grown in a pure culture fermentation that produces no antibiotics. They are fixed (rendered insoluble) for batch production with GRAS ingredients or may be fixed for further immobilization with either GRAS ingredients or materials approved under § 173.357 of this chapter.
( b ) The ingredient meets the general and additional requirements for enzyme preparations in the Food Chemicals Codex, 3d Ed. (1981), p. 107, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an enzyme, as defined in § 170.3(o)(9) of this chapter, to convert glucose to fructose.
( 2 ) The ingredient is used in high fructose corn syrup, at levels not to exceed current good manufacturing practice.
[48 FR 5720, Feb. 8, 1983, as amended at 61 FR 43450, Aug. 23, 1996]
<PAGE>   1
                                                                      EXHIBIT 24


                                POWER OF ATTORNEY

        Each director of Washington Banking Company (the "Company"), whose
signature appears below, hereby appoints Michal D. Cann, as his or her attorney
to sign, in his or her name and behalf and in any and all capacities stated
below, the Company's Registration Statement on Form S-8 (the "Registration
Statement(s)") for the registration of securities in connection with the
participation of directors and employees in and acquisition of securities
through the Whidbey Island Bank 401(k) Plan, and likewise to sign any and all
amendments and other documents relating thereto as shall be necessary to cause
the Registration Statements to become effective (including post-effective
amendments), and to sign any and all such documents upon the advice of legal
counsel to carry out the exercise and sale of the option shares, each such
person hereby granting to each such attorney power to act with or without the
other and full power of substitution and revocation, and hereby ratifying all of
that any such attorney or his substitute may do by virtue hereof.

        This Power of Attorney has been signed by the following persons in the
capacities indicated on the 18th day of June, 1998.


<TABLE>
<CAPTION>
        Signature                                                Title
        ---------                                                -----
<S>                                                              <C>
/s/  Michal D. Cann                                              Director
---------------------------
Michal D. Cann


/s/  Orlan Dean                                                  Director
---------------------------
Orlan Dean


/s/  Marlen Knutson                                              Director
---------------------------
Marlen Knutson


/s/  Karl C. Krieg, III                                          Director
---------------------------
Karl C. Krieg, III


/s/  Jay T. Lien                                                 Director
---------------------------
Jay T. Lien


/s/  Robert B. Olson                                             Director
---------------------------
Robert B. Olson


/s/  Anthony B. Pickering                                        Director
---------------------------
Anthony B. Pickering


/s/  Alvin J. Sherman                                            Director
---------------------------
Alvin J. Sherman


/s/  Edward J. Wallgren                                          Director
---------------------------
Edward J. Wallgren
</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1998             MAR-31-1997
<PERIOD-START>                             APR-01-1998             APR-01-1997
<PERIOD-END>                               SEP-30-1998             SEP-30-1997
<CASH>                                              20                     455
<SECURITIES>                                         0                       0
<RECEIVABLES>                                        0                       0
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                                     0                       0
<PP&E>                                               0                       0
<DEPRECIATION>                                       0                       0
<TOTAL-ASSETS>                                      20                     455
<CURRENT-LIABILITIES>                            7,350                   7,350
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                           15,000                  15,000
<PREFERRED>                                          0                       0
<COMMON>                                             0                       0
<OTHER-SE>                                    (22,330)                (21,895)
<TOTAL-LIABILITY-AND-EQUITY>                        20                     455
<SALES>                                              0                       0
<TOTAL-REVENUES>                                     0                       0
<CGS>                                                0                       0
<TOTAL-COSTS>                                       47                      84
<OTHER-EXPENSES>                                     0                       0
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                   0                       0
<INCOME-PRETAX>                                   (47)                    (84)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                                  0                       0
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                      (47)                    (84)
<EPS-PRIMARY>                                        0                       0
<EPS-DILUTED>                                        0                       0
        

</TABLE>
[Federal Register Volume 75, Number 35 (Tuesday, February 23, 2010)]
[Notices]
[Page 8043]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3501]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE


National Institute of Standards and Technology

AGENCY: National Institute of Standards and Technology, Commerce.

ACTION: Notice of Prospective Grant of Exclusive Patent License.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institute of Standards and 
Technology (``NIST''), U.S. Department of Commerce, is contemplating 
the grant of an exclusive license in the United States of America, its 
territories, possessions and commonwealths, to NIST's interest in the 
invention embodied in U.S. Patent No. 6,088,679 (Application No. 08/
980,908), titled ``Workflow Management Employing Role-based Access 
Control,'' NIST Docket No. 96-052 to Rockwise, Inc., having a place of 
business at 223 Surnac Circle, Morgantown, WV 26508. The grant of the 
license would be for the field of use: HealthCare Information 
Technology.

FOR FURTHER INFORMATION CONTACT: J. Terry Lynch, National Institute of 
Standards and Technology, Office of Technology Partnerships, 100 Bureau 
Drive, Stop 2200, Gaithersburg, MD 20899, Phone 301-975-2691.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be 
royalty bearing and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be 
granted unless, within thirty days from the date of this published 
Notice, NIST receives written evidence and argument which establish 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR 404.7. The availability of the 
invention for licensing was published in the Federal Register on March 
4, 1998.
    U.S. Patent No. 6,088,679 is owned by the U.S. government, as 
represented by the Secretary of Commerce. The patent involves a 
workflow sequence specified by a process definition that is managed by 
a workflow management system which enacts each segment in the order 
specified by that process definition. Role-based access control (RBAC) 
is used to define membership of individuals in groups, i.e., to assign 
individuals to roles, and to then activate the roles with respect to 
the process at appropriate points in the sequence. Any individual 
belonging to the active role can perform the next step in the business 
process. Changes in the duties and responsibilities of individuals as 
they change job assignments are greatly simplified, as their role 
memberships are simply reassigned; the workflow process is unaffected.

    Dated: February 17, 2010.
Marc G. Stanley,
Acting Deputy Director.
[FR Doc. 2010-3501 Filed 2-22-10; 8:45 am]
BILLING CODE 3510-13-P
###### Editorial Note on Part 172

#### Editorial Note:

Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 172.530 Disodium guanylate.

Disodium guanylate may be safely used as a flavor enhancer in foods, at a level not in excess of that reasonably required to produce the intended effect.
<TABLE> <S> <C>

<ARTICLE>                     5
<CIK>                         0000813621
<NAME>                        AMCOL International Corporation
<MULTIPLIER>                                   1,000
<CURRENCY>                                     USD
       
<S>                                            <C>
<PERIOD-TYPE>                                  3-MOS
<FISCAL-YEAR-END>                              DEC-31-1999
<PERIOD-START>                                 JAN-1-1999
<PERIOD-END>                                   MAR-31-1999
<EXCHANGE-RATE>                                1.00
<CASH>                                         6,284
<SECURITIES>                                   0
<RECEIVABLES>                                  96,986
<ALLOWANCES>                                   3,656
<INVENTORY>                                    47,632
<CURRENT-ASSETS>                               156,105
<PP&E>                                         329,533
<DEPRECIATION>                                 160,357
<TOTAL-ASSETS>                                 346,330
<CURRENT-LIABILITIES>                          67,787
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       320
<OTHER-SE>                                     0
<TOTAL-LIABILITY-AND-EQUITY>                   346,330
<SALES>                                        128,959
<TOTAL-REVENUES>                               128,959
<CGS>                                          98,606
<TOTAL-COSTS>                                  118,217
<OTHER-EXPENSES>                               9
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             1,869
<INCOME-PRETAX>                                8,864
<INCOME-TAX>                                   3,191
<INCOME-CONTINUING>                            5,739
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   5,739
<EPS-PRIMARY>                                  .21
<EPS-DILUTED>                                  .21
        


</TABLE>
**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the accompanying Quarterly Reporton Form 10-Q/A of Southwall Technologies Inc. (the “Company”), for the quarterended March 28, 2004, as filed with the Securities and Exchange Commissionon the date hereof (the “Report”), I, Thomas G. Hood, the Chief ExecutiveOfficer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,that:

1)   The Report fully complies with therequirements of Section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

2)   theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.
|        | September 7, 2004 | By:                       | /s/ Thomas G.  Hood |   |
|--------|------------------------|---------------------------|---------------------|--------|
|   |                   | Thomas G. Hood            |
|   | * *               | *Chief Executive Officer* |

 

A signed original of this written statement requiredby Section 906, or other document authenticating, acknowledging orotherwise adopting the signature that appears in typed form within theelectronic version of this written statement required by Section 906, hasbeen provided to the Company and will be retained by the Company and furnishedto the Securities and Exchange Commission or its staff upon request.

In accordance with Item 601 of Regulation S-K, thiscertification is being “furnished” as Exhibit 32.1 to the Company’squarterly report and shall not be deemed “filed” for purposes of Section 18of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwisesubject to the liabilities of that section, nor shall it be deemed incorporatedby reference in any filing under the Securities Act of 1933 or the Exchange Act,except as expressly set forth by specific reference in such a filing.

----